TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06789445: A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Sponsor: BlueRock Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 54 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$761,940

Rescue Site Savings

+$507,960

Unlock Full NCT06789445 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06789445 Rescue Dossier →